Symbols / TIVC Stock $0.97 +0.00% Tivic Health Systems, Inc.
TIVC (Stock) Chart
About
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 2.45M |
| Enterprise Value | -3.31M | Income | -7.99M | Sales | — |
| Book/sh | 6.65 | Cash/sh | 4.39 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -0.04 | PEG | — |
| P/S | — | P/B | 0.15 | P/C | — |
| EV/EBITDA | 0.42 | EV/Sales | — | Quick Ratio | 19.57 |
| Current Ratio | 20.13 | Debt/Eq | 38.42 | LT Debt/Eq | — |
| EPS (ttm) | -6.92 | EPS next Y | -24.00 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-11-14 16:00 | ROA | -28.69% |
| ROE | -82.69% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.88M |
| Shs Float | 2.50M | Short Float | 6.79% | Short Ratio | 0.34 |
| Short Interest | — | 52W High | 13.23 | 52W Low | 0.72 |
| Beta | 1.84 | Avg Volume | 231.69K | Volume | 208.00 |
| Target Price | — | Recom | None | Prev Close | $0.97 |
| Price | $0.97 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.95
Latest analyst target
3. DCF / Fair value
$-26.85
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.95
Low
—
High
—
Mean
—
- Tivic Health Systems Stock (TIVC) Opinions on Emerging Growth Conference Presentation - Quiver Quantitative hu, 02 Apr 2026 17
- TIVC Stock Price, Quote & Chart | TIVIC HEALTH SYSTEMS INC (NASDAQ:TIVC) - ChartMill hu, 02 Apr 2026 07
- Tivic Health (TIVC) director adds 19,000 shares in open-market buy - Stock Titan hu, 02 Apr 2026 13
- Valauri buys Tivic Health (TIVC) shares worth $18,008 - Investing.com hu, 02 Apr 2026 13
- Insider Purchase: Director at $TIVC Buys 19,000 Shares - Quiver Quantitative hu, 02 Apr 2026 14
- Insider Confidence Surges as Tivic Health Systems Director Doubles Down - TipRanks Fri, 03 Apr 2026 02
- New Tivic CEO to spotlight NIAID radiation study deal online - Stock Titan Fri, 27 Mar 2026 07
- TIVC | Tivic Health Systems, Inc. Financials - Income Statement - Quiver Quantitative hu, 02 Apr 2026 14
- Tivic shuts consumer business, builds immunotherapy and CDMO arms - Stock Titan Wed, 25 Mar 2026 07
- Tivic drops its sinus device to focus on radiation and cancer treatments - Stock Titan ue, 24 Mar 2026 07
- March 25 webcast: Tivic to outline 2025 year-end results - Stock Titan Fri, 20 Mar 2026 07
- U.S.-funded Tivic study targets deadly gut damage after radiation - Stock Titan hu, 26 Mar 2026 07
- Biotech leader behind 17 drug launches now steering Tivic’s biopharma pivot - Stock Titan Wed, 04 Mar 2026 08
- Tivic Health Systems (TIVC) CFO exercises restricted stock units into common shares - Stock Titan hu, 19 Mar 2026 07
- US reexamines Tivic radiation sickness drug that boosted survival in animals - Stock Titan Wed, 18 Feb 2026 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
-100.00%
|
1.18
-36.09%
|
1.84
|
| Operating Revenue |
|
0.00
|
0.00
-100.00%
|
1.18
-36.09%
|
1.84
|
| Cost Of Revenue |
|
—
|
0.78
-12.49%
|
0.89
-42.31%
|
1.54
|
| Reconciled Cost Of Revenue |
|
—
|
0.78
-12.49%
|
0.89
-42.31%
|
1.54
|
| Gross Profit |
|
—
|
0.00
-99.30%
|
0.29
-4.01%
|
0.30
|
| Operating Expense |
|
7.90
+76.45%
|
4.48
-47.54%
|
8.53
-17.94%
|
10.40
|
| Research And Development |
|
3.13
+138.46%
|
1.31
-20.66%
|
1.66
-4.34%
|
1.73
|
| Selling General And Administration |
|
4.77
+50.71%
|
3.16
-54.01%
|
6.88
-20.65%
|
8.67
|
| Selling And Marketing Expense |
|
—
|
1.19
-44.14%
|
2.12
-23.89%
|
2.79
|
| General And Administrative Expense |
|
4.77
+50.71%
|
3.16
-33.44%
|
4.75
-19.11%
|
5.88
|
| Other Gand A |
|
4.77
+50.71%
|
3.16
-33.44%
|
4.75
-19.11%
|
5.88
|
| Total Expenses |
|
7.90
+76.45%
|
4.48
-52.49%
|
9.42
-21.08%
|
11.94
|
| Operating Income |
|
-7.90
-76.45%
|
-4.48
+45.71%
|
-8.24
+18.35%
|
-10.10
|
| Total Operating Income As Reported |
|
-7.90
-76.45%
|
-4.48
+45.71%
|
-8.24
+18.35%
|
-10.10
|
| EBITDA |
|
-7.84
-90.43%
|
-4.12
+48.93%
|
-8.06
+18.75%
|
-9.92
|
| Normalized EBITDA |
|
-7.87
-91.11%
|
-4.12
+48.93%
|
-8.06
+18.75%
|
-9.92
|
| Reconciled Depreciation |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| EBIT |
|
-7.85
-75.55%
|
-4.47
+45.79%
|
-8.24
+18.35%
|
-10.10
|
| Total Unusual Items |
|
0.03
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
0.03
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Pretax Income |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Non Operating Interest Income Expense |
|
-0.12
-2150.00%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Expense Non Operating |
|
0.15
|
0.00
|
—
|
—
|
| Net Interest Income |
|
-0.12
-2150.00%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Expense |
|
0.15
|
0.00
|
—
|
—
|
| Interest Income Non Operating |
|
0.02
+283.33%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Interest Income |
|
0.02
+283.33%
|
0.01
+500.00%
|
0.00
-50.00%
|
0.00
|
| Other Income Expense |
|
0.03
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
—
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.03
|
—
|
—
|
—
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Net Income From Continuing Operation Net Minority Interest |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income From Continuing And Discontinued Operation |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Continuous Operations |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Discontinuous Operations |
|
-0.89
+25.32%
|
-1.19
|
—
|
—
|
| Normalized Income |
|
-8.02
-79.44%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Net Income Common Stockholders |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Diluted EPS |
|
—
|
-19.68
+88.87%
|
-176.80
+90.00%
|
-1,768.00
|
| Basic EPS |
|
—
|
-19.68
+88.87%
|
-176.80
+90.00%
|
-1,768.00
|
| Basic Average Shares |
|
—
|
0.29
+516.01%
|
0.05
+720.00%
|
0.01
|
| Diluted Average Shares |
|
—
|
0.29
+516.01%
|
0.05
+720.00%
|
0.01
|
| Diluted NI Availto Com Stockholders |
|
-8.88
-56.99%
|
-5.66
+31.40%
|
-8.24
+18.34%
|
-10.10
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.00
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
5.16
|
| Current Assets |
|
4.65
|
| Cash Cash Equivalents And Short Term Investments |
|
3.40
|
| Cash And Cash Equivalents |
|
3.40
|
| Receivables |
|
0.17
|
| Accounts Receivable |
|
0.17
|
| Gross Accounts Receivable |
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
—
|
| Inventory |
|
0.76
|
| Raw Materials |
|
0.75
|
| Work In Process |
|
0.00
|
| Finished Goods |
|
0.04
|
| Prepaid Assets |
|
—
|
| Current Deferred Assets |
|
0.00
|
| Assets Held For Sale Current |
|
—
|
| Other Current Assets |
|
0.33
|
| Total Non Current Assets |
|
0.51
|
| Net PPE |
|
0.47
|
| Gross PPE |
|
0.51
|
| Accumulated Depreciation |
|
-0.04
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
0.35
|
| Machinery Furniture Equipment |
|
0.01
|
| Other Properties |
|
0.15
|
| Goodwill And Other Intangible Assets |
|
—
|
| Other Intangible Assets |
|
—
|
| Non Current Deferred Assets |
|
0.00
|
| Other Non Current Assets |
|
0.03
|
| Total Liabilities Net Minority Interest |
|
1.58
|
| Current Liabilities |
|
1.40
|
| Payables And Accrued Expenses |
|
1.21
|
| Payables |
|
0.87
|
| Accounts Payable |
|
0.71
|
| Current Accrued Expenses |
|
0.34
|
| Total Tax Payable |
|
0.16
|
| Current Debt And Capital Lease Obligation |
|
0.19
|
| Current Capital Lease Obligation |
|
0.19
|
| Other Current Liabilities |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.18
|
| Liabilities Heldfor Sale Non Current |
|
—
|
| Long Term Debt And Capital Lease Obligation |
|
0.18
|
| Long Term Debt |
|
—
|
| Long Term Capital Lease Obligation |
|
0.18
|
| Other Non Current Liabilities |
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
3.58
|
| Common Stock Equity |
|
3.58
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.09
|
| Ordinary Shares Number |
|
0.09
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
41.47
|
| Retained Earnings |
|
-37.89
|
| Total Equity Gross Minority Interest |
|
3.58
|
| Total Capitalization |
|
3.58
|
| Working Capital |
|
3.25
|
| Invested Capital |
|
3.58
|
| Total Debt |
|
0.37
|
| Capital Lease Obligations |
|
0.37
|
| Net Tangible Assets |
|
3.58
|
| Tangible Book Value |
|
3.58
|
| Derivative Product Liabilities |
|
—
|
| Inventories Adjustments Allowances |
|
-0.03
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.00
-22.25%
|
-5.72
+32.73%
|
-8.51
+4.57%
|
-8.92
|
| Cash Flow From Continuing Operating Activities |
|
-6.62
-30.24%
|
-5.08
+40.29%
|
-8.51
+4.57%
|
-8.92
|
| Cash From Discontinued Operating Activities |
|
-0.38
+40.90%
|
-0.64
|
—
|
—
|
| Net Income From Continuing Operations |
|
-7.99
-78.81%
|
-4.47
+45.78%
|
-8.24
+18.34%
|
-10.10
|
| Depreciation Amortization Depletion |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Depreciation |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Depreciation And Amortization |
|
0.01
-98.58%
|
0.35
+93.41%
|
0.18
+4.60%
|
0.17
|
| Other Non Cash Items |
|
0.24
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.56
+146.29%
|
0.23
-15.50%
|
0.27
-31.91%
|
0.40
|
| Provisionand Write Offof Assets |
|
—
|
0.35
+1006.25%
|
0.03
|
0.00
|
| Asset Impairment Charge |
|
0.14
|
0.00
|
—
|
—
|
| Operating Gains Losses |
|
-0.03
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-0.03
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.45
+137.89%
|
-1.19
-58.64%
|
-0.75
-224.30%
|
0.60
|
| Change In Receivables |
|
—
|
0.10
+256.72%
|
-0.07
-6800.00%
|
0.00
|
| Changes In Account Receivables |
|
—
|
0.10
+256.72%
|
-0.07
-6800.00%
|
0.00
|
| Change In Inventory |
|
—
|
0.08
+10.67%
|
0.07
+117.28%
|
-0.43
|
| Change In Prepaid Assets |
|
0.08
+0.00%
|
0.08
+184.78%
|
-0.09
-116.49%
|
0.56
|
| Change In Payables And Accrued Expense |
|
0.37
+139.96%
|
-0.94
-84.62%
|
-0.51
-178.85%
|
0.64
|
| Change In Accrued Expense |
|
0.23
+167.53%
|
-0.35
-437.86%
|
0.10
-5.50%
|
0.11
|
| Change In Payable |
|
0.14
+123.64%
|
-0.59
+3.61%
|
-0.61
-214.23%
|
0.53
|
| Change In Account Payable |
|
0.14
+123.64%
|
-0.59
+3.61%
|
-0.61
-214.23%
|
0.53
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
0.03
|
0.00
-100.00%
|
0.01
|
| Change In Other Current Liabilities |
|
0.00
+100.00%
|
-0.37
-129.19%
|
-0.16
+9.55%
|
-0.18
|
| Investing Cash Flow |
|
-0.70
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Cash Flow From Continuing Investing Activities |
|
-0.70
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Net PPE Purchase And Sale |
|
-0.04
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Purchase Of PPE |
|
-0.04
|
0.00
+100.00%
|
-0.12
-972.73%
|
-0.01
|
| Capital Expenditure |
|
-0.58
|
—
|
-0.12
-972.73%
|
-0.01
|
| Net Investment Purchase And Sale |
|
-0.12
|
0.00
|
—
|
—
|
| Purchase Of Investment |
|
-0.12
|
0.00
|
—
|
—
|
| Net Intangibles Purchase And Sale |
|
-0.54
|
0.00
|
—
|
—
|
| Purchase Of Intangibles |
|
-0.54
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
18.35
+323.52%
|
4.33
-49.08%
|
8.51
+1711.17%
|
-0.53
|
| Cash Flow From Continuing Financing Activities |
|
18.35
+323.52%
|
4.33
-49.08%
|
8.51
+1711.17%
|
-0.53
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
—
|
0.00
|
| Repayment Of Debt |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Net Common Stock Issuance |
|
2.34
-46.66%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.11
|
0.00
|
0.00
-100.00%
|
0.06
|
| Net Other Financing Charges |
|
-0.31
-528.57%
|
-0.05
|
—
|
-0.58
|
| Changes In Cash |
|
10.64
+864.03%
|
-1.39
-1041.80%
|
-0.12
+98.71%
|
-9.46
|
| Beginning Cash Position |
|
2.00
-41.03%
|
3.40
-3.47%
|
3.52
-72.89%
|
12.97
|
| End Cash Position |
|
12.64
+531.62%
|
2.00
-41.03%
|
3.40
-3.47%
|
3.52
|
| Free Cash Flow |
|
-7.58
-32.40%
|
-5.72
+33.65%
|
-8.63
+3.37%
|
-8.93
|
| Interest Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Common Stock Issuance |
|
2.34
-46.66%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Issuance Of Capital Stock |
|
18.55
+323.33%
|
4.38
-48.50%
|
8.51
|
0.00
|
| Net Preferred Stock Issuance |
|
16.21
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
16.21
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-02 View
- 10-K2026-03-30 View
- 8-K2026-03-25 View
- 8-K2026-03-20 View
- 42026-03-19 View
- 8-K2026-03-13 View
- 8-K2026-03-11 View
- 8-K2026-03-04 View
- 42026-02-20 View
- 8-K2026-02-09 View
- 8-K2026-01-20 View
- 42025-12-22 View
- 42025-12-22 View
- 8-K2025-12-11 View
- 8-K2025-11-18 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 8-K2025-11-13 View
- 8-K2025-10-15 View
- 42025-09-24 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|